EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Acellular Human Amniotic Fluid-Derived Extracellular Vesicles as Novel Anti-Inflammatory Therapeutics against SARS-CoV-2 Infection

Debarati Chanda iD, Tania Del Rivero iD, Roshan Ghimire iD, Sunil More, Maria Ines Mitrani iD, Michael A Bellio, Rudragouda Channappanavar

Viruses · 2024

DOI: 10.3390/v16020273 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Debarati Chanda und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Pathobiology, Oklahoma State University, Stillwater, OK 74078, USA. Hauptthemen laut MEDLINE: COVID-19, Respiratory Distress Syndrome, Extracellular Vesicles, Biological Products. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, Organicell, Oklahoma State University College of Veterinary Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ongoing COVID-19 pandemic caused by SARS-CoV-2 is associated with acute respiratory distress syndrome (ARDS) and fatal pneumonia. Excessive inflammation caused by SARS-CoV-2 is the key driver of ARDS and lethal disease. Several FDA-approved drugs that suppress virus replication are in clinical use. However, despite strong evidence for the role of virus-induced inflammation in severe COVID-19, no effective anti-inflammatory drug is available to control fatal inflammation as well as efficiently clear the virus. Therefore, there is an urgent need to identify biologically derived immunomodulators that suppress inflammation and promote antiviral immunity. In this study, we evaluated acellular human amniotic fluid (acAF) containing extracellular vesicles (hAF-EVs) as a potential non-toxic and safe biologic for immunomodulation during COVID-19. Our in vitro results showed that acAF significantly reduced inflammatory cytokine production in TLR2/4/7 and SARS-CoV-2 structural protein-stimulated mouse macrophages. Importantly, an intraperitoneal administration of acAF reduced morbidity and mortality in SARS-CoV-2-infected mice. A detailed examination of SARS-CoV-2-infected lungs revealed that the increased protection in acAF-treated mice was associated with reduced viral titers and levels of inflammatory myeloid cell infiltration. Collectively, our results identify a novel biologic that has potential to suppress excessive inflammation and enhance survival following SARS-CoV-2 infection, highlighting the translational potential of acAF against COVID-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Respiratory Distress SyndromeExtracellular VesiclesBiological ProductsHumansAnimalsMiceSARS-CoV-2Amniotic FluidPandemicsInflammationAnti-Inflammatory Agents

Stichwörter der Autor:innen

AF-EVsMA-CoV-2acAFcytokine stormdysregulated immunitymyeloid cells

Substanzen

Anti-Inflammatory AgentsBiological Products

Autor:innen und Institutionen

  • Department of Veterinary Pathobiology, Oklahoma State University, Stillwater, OK 74078, USA.
  • Organicell Regenerative Medicine, Davie, FL 33314, USA.

ORCID-Profile: Debarati Chanda, Tania Del Rivero, Roshan Ghimire, Maria Ines Mitrani

Förderung

  • NIH HHS
  • Organicell
  • Oklahoma State University College of Veterinary Medicine

Zitieren

APA

Chanda, D., Del Rivero, T., Ghimire, R., More, S., Mitrani, M. I., Bellio, M. A., & Channappanavar, R. (2024). Acellular Human Amniotic Fluid-Derived Extracellular Vesicles as Novel Anti-Inflammatory Therapeutics against SARS-CoV-2 Infection. Viruses. https://doi.org/10.3390/v16020273

Vancouver

Chanda D, Del Rivero T, Ghimire R, More S, Mitrani MI, Bellio MA, et al. Acellular Human Amniotic Fluid-Derived Extracellular Vesicles as Novel Anti-Inflammatory Therapeutics against SARS-CoV-2 Infection. Viruses. 2024. doi:10.3390/v16020273

BibTeX
@article{Chanda2024,
  author = {Chanda, Debarati and Del Rivero, Tania and Ghimire, Roshan and More, Sunil and Mitrani, Maria Ines and Bellio, Michael A and Channappanavar, Rudragouda},
  title = {Acellular Human Amniotic Fluid-Derived Extracellular Vesicles as Novel Anti-Inflammatory Therapeutics against SARS-CoV-2 Infection},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16020273}
}
Kostenlos starten →